Opiant Pharmaceuticals, Inc. (OPNT) |
| 20.65 0 (0%) 03-01 16:00 |
| Open: | 20.8765 |
| High: | 20.94 |
| Low: | 20.56 |
| Volume: | 562,778 |
| Market Cap: | 109(M) |
| PE Ratio: | -3.16 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 22.43 |
| Resistance 1: | 19.26 |
| Pivot price: | 15.83 |
| Support 1: | 14.13 |
| Support 2: | 11.76 |
| 52w High: | 27.36 |
| 52w Low: | 7.34 |
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
Financials
| EPS | 0.150 |
| Book Value | 12.180 |
| PEG Ratio | 0.00 |
| Gross Profit | 9.186 |
| Profit Margin (%) | 0.71 |
| Operating Margin (%) | -4.05 |
| Return on Assets (ttm) | 1.1 |
| Return on Equity (ttm) | 1.2 |
Company news
Thu, 24 Apr 2025
OPNT Stock Price, News & Analysis - Stock Titan
Thu, 02 Mar 2023
Indivior Completes Acquisition of Opiant Pharmaceuticals, Inc. - PR Newswire
Tue, 06 Dec 2022
U.S. FDA to review Emergent's OTC opioid overdose drug on priority - Reuters
Mon, 14 Nov 2022
Indivior PLC to Acquire Opiant Pharmaceuticals - Yahoo Finance
Mon, 14 Nov 2022
Indivior To Acquire Opiant Pharmaceuticals - PR Newswire
Thu, 08 Jul 2021
These stocks have an unusual volume in today's session - ChartMill
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
